Moderna — 2026Q3 财报

来自财报

An EPS beat that is a cost story, not a demand story: revenue was about $0.1 billion against a $(0.8) billion GAAP net loss, and what improved was the expense outlook and the year-end cash range, while full-year growth guidance was only reiterated. The release pairs a near-term approval catalyst (mFLUSIVA's August 5 PDUFA date, which would be a fifth approved product) with a Phase 3 interim miss on norovirus — and puts both in the headline block rather than burying the setback.

• “Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97)”

  The quarter was a GAAP loss on ~$0.1bn of revenue — the top line, not the cost line, is the problem.

  来源 ↗

• “Reiterates plan to deliver up to 10% revenue growth in 2026”

  Full-year growth guidance was reiterated rather than raised.

  来源 ↗

• “Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.7 - 5.2 billion”

  The good news is cost and cash, not demand: opex outlook improved ~$0.2bn and the year-end cash range moved up.

  来源 ↗

• “Anticipates potential approval of Moderna's fifth product with the August 5th PDUFA date for mFLUSIVA, the Company's seasonal influenza vaccine candidate”

  A fifth approved product was in reach at the PDUFA date days after this release.

  来源 ↗

• “Announces that mRNA-1403, Moderna's norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis and the Company is preparing to enroll an additional cohort”

  The pipeline setback is stated in the headline block, not buried: norovirus missed its Phase 3 interim bar.

  来源 ↗